RPH3AL

Across TCGA pan-cancer cohorts, RPH3AL Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated RPH3AL data layer compared with 22 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher RPH3AL Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated RPH3AL expression acts as an unfavorable survival marker.

ACC, HNSC, and KIRC are the cancer types where RPH3AL Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.046	0.753	<.001	36	view →
HNSC	OS	Median	All	0.146	0.768	<.001	24	view →
KIRC	OS	Median	All	0.127	0.874	<.001	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
LUAD	OS	Median	All	0.276	0.697	.043	3	view →
SKCM	OS	Median	All	0.636	0.875	.030	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

RPH3AL–ACC (DFS)

Open the ACC breakdown →